Fisher Asset Management LLC Lowers Holdings in Iqvia Holdings Inc (IQV)

Fisher Asset Management LLC reduced its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 28.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 79,797 shares of the medical research company’s stock after selling 31,496 shares during the period. Fisher Asset Management LLC’s holdings in Iqvia were worth $10,353,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. USS Investment Management Ltd purchased a new stake in Iqvia during the third quarter worth about $86,508,000. Steward Partners Investment Advisory LLC boosted its holdings in Iqvia by 250.1% during the third quarter. Steward Partners Investment Advisory LLC now owns 10,267 shares of the medical research company’s stock worth $1,332,000 after buying an additional 7,334 shares in the last quarter. Telemus Capital LLC purchased a new stake in Iqvia during the third quarter worth about $232,000. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its holdings in Iqvia by 144.5% during the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 30,257 shares of the medical research company’s stock worth $3,936,000 after buying an additional 17,882 shares in the last quarter. Finally, Three Peaks Capital Management LLC purchased a new stake in Iqvia during the third quarter worth about $2,376,000. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Shares of IQV opened at $120.81 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41. The stock has a market cap of $24.32 billion, a price-to-earnings ratio of 27.71, a price-to-earnings-growth ratio of 1.72 and a beta of 0.70. Iqvia Holdings Inc has a 12-month low of $91.57 and a 12-month high of $135.48.



Iqvia (NYSE:IQV) last announced its earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.03. The company had revenue of $2.59 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The company’s revenue was up 5.2% on a year-over-year basis. As a group, research analysts anticipate that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

A number of analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of Iqvia from $143.00 to $146.00 and gave the stock an “outperform” rating in a report on Tuesday, October 2nd. UBS Group assumed coverage on shares of Iqvia in a report on Tuesday, October 9th. They set a “buy” rating on the stock. Raymond James boosted their price objective on shares of Iqvia from $136.00 to $145.00 and gave the stock a “strong-buy” rating in a report on Friday, August 31st. Argus set a $136.00 price objective on shares of Iqvia and gave the stock a “buy” rating in a report on Thursday, August 23rd. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $97.00 price objective on shares of Iqvia in a report on Wednesday, July 25th. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $131.32.

In other news, insider Robert Parks sold 871 shares of the business’s stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $124.34, for a total value of $108,300.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John G. Danhakl sold 370,470 shares of the business’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total transaction of $46,245,770.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 602,457 shares of company stock valued at $75,618,723. 6.00% of the stock is currently owned by company insiders.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Hedge Funds

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply